TNGX צמיחת רווח נקי למניה השנה Tango Therapeutics

Tango Therapeutics (TNGX) develops R&D projects through alliances with pharma giants, excluding mergers. The business relies on a synthetic lethality platform that creates unique patent perimeters. The synergy of these factors and a qualified staff of oncologists determine the annual EPS growth rate, where the current value is -72.40, demonstrating the company's efficiency dynamics.

For Tango Therapeutics (TNGX), as an R&D startup with oncology partnerships, profit dynamics are secondary to clinical trial progress. By analyzing the 12-month EPS growth percentage, an investor assesses the annual change in net income per share, which allows this chart to track cost management efficiency and the sustainability of the financial trend in the absence of commercial sales.